source
- Amgen deploys patients to defend troubled Tavneos in FDA hearing requestFacing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.BioSpace · 5d ago↗ source
- STAT+: Fatal gene-editing trial in China raises ethics and oversight questionsSanofi insulin pen in short supply, a win for peptide compounds, and more biotech news from The ReadoutSTAT · 5d ago↗ source
- STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and moreIn a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugsSTAT